Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Does nipple sparing mastectomy affect the postoperative complication rate after breast reconstruction? Comparison of postoperative complications after nipple sparing mastectomy vs skin sparing mastectomy.

Kracoff S, Benkler M, Allweis TM, Ben-Baruch N, Egozi D.

Breast J. 2019 Jul;25(4):755-756. doi: 10.1111/tbj.13325. Epub 2019 May 7. No abstract available.

PMID:
31066148
2.

Neo-adjuvant chemotherapy does not affect the immediate postoperative complication rate after breast reconstruction.

Kracoff S, Allweis TM, Ben-Baruch N, Benkler M, Fadi S, Egozi D.

Breast J. 2019 May;25(3):528-530. doi: 10.1111/tbj.13277. Epub 2019 Apr 9. No abstract available.

PMID:
30964213
3.

Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial.

Delaloge S, Cella D, Ye Y, Buyse M, Chan A, Barrios CH, Holmes FA, Mansi J, Iwata H, Ejlertsen B, Moy B, Chia SKL, Gnant M, Smichkoska S, Ciceniene A, Martinez N, Filipović S, Ben-Baruch NE, Joy AA, Langkjer ST, Senecal F, de Boer RH, Moran S, Yao B, Bryce R, Auerbach A, Fallowfield L, Martin M.

Ann Oncol. 2019 Apr 1;30(4):567-574. doi: 10.1093/annonc/mdz016.

PMID:
30689703
4.

Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry.

Stemmer SM, Steiner M, Rizel S, Soussan-Gutman L, Ben-Baruch N, Bareket-Samish A, Geffen DB, Nisenbaum B, Isaacs K, Fried G, Rosengarten O, Uziely B, Svedman C, McCullough D, Maddala T, Klang SH, Zidan J, Ryvo L, Kaufman B, Evron E, Karminsky N, Goldberg H, Shak S, Liebermann N.

NPJ Breast Cancer. 2017 Sep 8;3:33. doi: 10.1038/s41523-017-0034-6. eCollection 2017.

5.

Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry.

Stemmer SM, Steiner M, Rizel S, Geffen DB, Nisenbaum B, Peretz T, Soussan-Gutman L, Bareket-Samish A, Isaacs K, Rosengarten O, Fried G, McCullough D, Svedman C, Shak S, Liebermann N, Ben-Baruch N.

NPJ Breast Cancer. 2017 Sep 8;3:32. doi: 10.1038/s41523-017-0033-7. eCollection 2017.

6.

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16/NOVA Investigators.

N Engl J Med. 2016 Dec 1;375(22):2154-2164. Epub 2016 Oct 7.

7.

Identification and Characterization of a Novel Aspergillus fumigatus Rhomboid Family Putative Protease, RbdA, Involved in Hypoxia Sensing and Virulence.

Vaknin Y, Hillmann F, Iannitti R, Ben Baruch N, Sandovsky-Losica H, Shadkchan Y, Romani L, Brakhage A, Kniemeyer O, Osherov N.

Infect Immun. 2016 May 24;84(6):1866-1878. doi: 10.1128/IAI.00011-16. Print 2016 Jun.

8.

HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.

Ben-Baruch NE, Bose R, Kavuri SM, Ma CX, Ellis MJ.

J Natl Compr Canc Netw. 2015 Sep;13(9):1061-4.

9.

D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer.

Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, Dvir A, Soussan-Gutman L, Jeselsohn R, Yelensky R, Brown M, Miller VA, Sarid D, Rizel S, Klein B, Rubinek T, Wolf I.

Cancer Res. 2013 Dec 1;73(23):6856-64. doi: 10.1158/0008-5472.CAN-13-1197. Epub 2013 Nov 11.

10.

The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients.

Stemmer SM, Klang SH, Ben-Baruch N, Geffen DB, Steiner M, Soussan-Gutman L, Merling S, Svedman C, Rizel S, Lieberman N.

Breast Cancer Res Treat. 2013 Jul;140(1):83-92. doi: 10.1007/s10549-013-2603-1. Epub 2013 Jun 26.

11.

Pretreatment CA 15-3 levels do not predict disease-free survival in patients with advanced epithelial ovarian cancer.

Gemer O, Oustinov N, Gdalevich M, Dubnik S, Levy R, Yachnin A, Lavie O, Ben Baruch N, Ben Arie A.

Tumori. 2013 Mar-Apr;99(2):257-60. doi: 10.1700/1283.14201.

PMID:
23748823
12.

Facial swelling and somnolence in a patient with cancer.

Schattner A, Ben-Baruch N, Adi M.

QJM. 2013 Mar;106(3):283-4. doi: 10.1093/qjmed/hcr268. Epub 2012 Jan 5. No abstract available.

PMID:
22223672
13.

Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel.

Laitman Y, Borsthein RT, Stoppa-Lyonnet D, Dagan E, Castera L, Goislard M, Gershoni-Baruch R, Goldberg H, Kaufman B, Ben-Baruch N, Zidan J, Maray T, Soussan-Gutman L, Friedman E.

Breast Cancer Res Treat. 2011 Jun;127(2):489-95. doi: 10.1007/s10549-010-1217-0. Epub 2010 Oct 20.

PMID:
20960228
14.

Hormone receptor expression is associated with a unique pattern of metastatic spread and increased survival among HER2-overexpressing breast cancer patients.

Paluch-Shimon S, Ben-Baruch N, Wolf I, Zach L, Kopolovic J, Kruglikova A, Modiano T, Yosepovich A, Catane R, Kaufman B.

Am J Clin Oncol. 2009 Oct;32(5):504-8. doi: 10.1097/COC.0b013e3181967d72.

PMID:
19564785
15.

Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study.

Wolf I, Ben-Baruch N, Shapira-Frommer R, Rizel S, Goldberg H, Yaal-Hahoshen N, Klein B, Geffen DB, Kaufman B.

Cancer. 2008 Feb 15;112(4):731-6.

16.

Malignant ascites and bacterial peritonitis.

Schattner A, Ben-Baruch N.

Med J Aust. 2006 Jan 16;184(2):92-3. No abstract available.

PMID:
16411880
17.

Postoperative loco-regional radiation therapy for breast cancer patients with four or more involved lymph nodes or extracapsular extension.

Evron E, Barzily L, Rakowsky E, Ben-Baruch N, Sulkes J, Rizel S, Fenig E.

Isr Med Assoc J. 2005 Jul;7(7):439-42.

18.

Prenatal diagnosis in Li-Fraumeni syndrome.

Avigad S, Peleg D, Barel D, Benyaminy H, Ben-Baruch N, Taub E, Shohat M, Goshen Y, Cohen IJ, Yaniv I, Zaizov R.

J Pediatr Hematol Oncol. 2004 Sep;26(9):541-5.

PMID:
15342977
19.

Oncogenes in male breast cancer.

Idelevich E, Mozes M, Ben-Baruch N, Huszar M, Kruglikova A, Katsnelson R, Shani A.

Am J Clin Oncol. 2003 Jun;26(3):259-61.

PMID:
12796596
20.

Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients.

Stemmer SM, Hardan I, Raz H, Adamou AK, Inbar M, Gottfried M, Merrick Y, Cohen Y, Sulkes A, Ben-Baruch N, Pfeffer RP, Brenner HJ, Rizel S.

Bone Marrow Transplant. 2003 Apr;31(8):655-61.

PMID:
12692605
21.

Diagnostic dilemmas in oncology. Case 2. Umbilical metastasis as the presenting symptom of non-cell lung cancer.

Idelevich E, Husar M, Fenig E, Brenner B, Ben-Baruch N, Adi S.

J Clin Oncol. 2000 Sep;18(17):3188-9. No abstract available.

PMID:
10963648
22.

Induction of Myc-intron-binding polypeptides MIBP1 and RFX1 during retinoic acid-mediated differentiation of haemopoietic cells.

Zajac-Kaye M, Ben-Baruch N, Kastanos E, Kaye FJ, Allegra C.

Biochem J. 2000 Feb 1;345 Pt 3:535-41.

23.

An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4.

Chen X, Levkowitz G, Tzahar E, Karunagaran D, Lavi S, Ben-Baruch N, Leitner O, Ratzkin BJ, Bacus SS, Yarden Y.

J Biol Chem. 1996 Mar 29;271(13):7620-9.

24.

c-myc Down-regulation in suramin-treated HL60 cells precedes growth inhibition but does not trigger differentiation.

Ben-Baruch N, Reinhold WC, Alexandrova N, Ichinose I, Blake M, Trepel JB, Zajac-Kaye M.

Mol Pharmacol. 1994 Jul;46(1):73-8.

PMID:
8058059
25.

Neu differentiation factors: a family of alternatively spliced neuronal and mesenchymal factors.

Ben-Baruch N, Yarden Y.

Proc Soc Exp Biol Med. 1994 Jul;206(3):221-7. Review.

PMID:
7912439
26.

Structural and functional aspects of the multiplicity of Neu differentiation factors.

Wen D, Suggs SV, Karunagaran D, Liu N, Cupples RL, Luo Y, Janssen AM, Ben-Baruch N, Trollinger DB, Jacobsen VL, et al.

Mol Cell Biol. 1994 Mar;14(3):1909-19.

27.

Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors.

Bacus SS, Gudkov AV, Zelnick CR, Chin D, Stern R, Stancovski I, Peles E, Ben-Baruch N, Farbstein H, Lupu R, et al.

Cancer Res. 1993 Nov 1;53(21):5251-61.

28.

Second-line chemotherapy with mitoxantrone as a single agent in metastatic breast cancer.

Brufman G, Haim N, Ben-Baruch N, Sulkes A.

J Chemother. 1993 Feb;5(1):43-6.

PMID:
8459264
29.

Phase II study of fazarabine (NSC 281272) in patients with metastatic colon cancer.

Ben-Baruch N, Denicoff AM, Goldspiel BR, O'Shaughnessy JA, Cowan KH.

Invest New Drugs. 1993 Feb;11(1):71-4.

PMID:
7688714
30.

The effect of systemic therapy on local-regional control in locally advanced breast cancer.

Pierce LJ, Lippman M, Ben-Baruch N, Swain S, O'Shaughnessy J, Bader JL, Danforth D, Venzon D, Cowan KH.

Int J Radiat Oncol Biol Phys. 1992;23(5):949-60.

PMID:
1639655
31.

Radiation therapy for locally advanced breast cancer: prognostic factors and complication rate.

Weshler Z, Brufman G, Sulkes A, Warner-Efraty E, Ben-Baruch N, Biran S, Fuks Z.

Eur J Surg Oncol. 1990 Oct;16(5):430-5.

PMID:
2209839
32.

The use of monoclonal anti-CEA antibody immunohistochemistry in detecting the origin of oral cavity metastasis.

Nitzan DW, Livni N, Marmary Y, Ben-Baruch N, Sela J, Catane R.

Int J Oral Maxillofac Surg. 1990 Jun;19(3):162-4.

PMID:
2114461
33.

Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272).

Surbone A, Ford H Jr, Kelley JA, Ben-Baruch N, Thomas RV, Fine R, Cowan KH.

Cancer Res. 1990 Feb 15;50(4):1220-5.

34.

Downstream regulatory elements in the c-myc gene.

Zajac-Kaye M, Yu B, Ben-Baruch N.

Curr Top Microbiol Immunol. 1990;166:279-84. No abstract available.

PMID:
2073807
35.

Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study.

Gabizon A, Peretz T, Sulkes A, Amselem S, Ben-Yosef R, Ben-Baruch N, Catane R, Biran S, Barenholz Y.

Eur J Cancer Clin Oncol. 1989 Dec;25(12):1795-803.

PMID:
2632261
36.

Methylprednisolone and chlorpromazine in patients receiving cancer chemotherapy: a prospective non-randomized study.

Gez E, Brufman G, Kaufman B, Yitzhaki N, Gera C, Ben-Baruch N, Sulkes A, Biran S.

J Chemother. 1989 Apr;1(2):140-3.

PMID:
2732782
37.

Malignant melanoma of the uterine cervix: case report and review of the literature.

Mordel N, Mor-Yosef S, Ben-Baruch N, Anteby SO.

Gynecol Oncol. 1989 Mar;32(3):375-80. Review.

PMID:
2646184
38.

Concurrence of ovarian cancer and dermatomyositis. A report of two cases and literature review.

Mordel N, Margalioth EJ, Harats N, Ben-Baruch N, Schenker JG.

J Reprod Med. 1988 Jul;33(7):649-55. Review.

PMID:
3050072
39.

Combined immunotherapy and chemotherapy with tuftsin plus cyclophosphamide in the treatment of non-small-cell carcinoma of the lung.

Warner E, Sulkes A, Gez E, Uziely B, Ben-Baruch N, Ben-Yosef R, Biran S, Catane R.

Chemioterapia. 1987 Jun;6(2 Suppl):706-8. No abstract available.

PMID:
2855624
40.

High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study.

Gez E, Warner-Efraty E, Ben-Yosef R, Ben-Baruch N, Yitzhaki N, Uziely B, Brufman G, Biran S.

Oncology. 1987;44(4):237-9.

PMID:
3614813
41.

Cerastes vipera envenoming--a report of seven cases.

Ben-Baruch N, Porath A, Kleiner-Baumgarten A, Keynan A.

Trans R Soc Trop Med Hyg. 1986;80(4):664. No abstract available.

PMID:
3810801
42.

Neutropenia induced by hypercarotenaemia.

Shoenfeld Y, Shaklai M, Ben-Baruch N, Hirschorn M, Pinkhaus J.

Lancet. 1982 May 29;1(8283):1245. No abstract available.

PMID:
6122999
43.

Carbamazepine (Tegretol)-induced thrombocytopenia.

Shoenfeld Y, Ben Baruch N, Livni E, Santo M, Pinkhas J.

Acta Haematol. 1982;68(1):74. No abstract available.

Supplemental Content

Loading ...
Support Center